Cyr61 promotes epithelial-mesenchymal transition and tumor metastasis of osteosarcoma by Raf-1/MEK/ERK/Elk-1/TWIST-1 signaling pathway

Molecular Cancer

Volumn 13, Issue 1, 2014, Pages

  Hou, Chun Han ^a   Lin, Feng Ling ^b   Hou, Sheng Mon ^c   Liu, Ju Fang ^c  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b CATHAY GENERAL HOSPITAL   (Taiwan)

^c SHIN KONG WU HO SU MEMORIAL HOSPITAL   (Taiwan)

Author keywords

Cyr61; EMT; Migration; Osteosarcoma

Indexed keywords

ALPHAVBETA5 INTEGRIN; CYSTEINE RICH PROTEIN 61; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE; NERVE CELL ADHESION MOLECULE; PROTEIN TWIST 1; RAF PROTEIN; TRANSCRIPTION FACTOR ELK 1; TRANSCRIPTION FACTOR TWIST; UNCLASSIFIED DRUG; UVOMORULIN; TUMOR MARKER; VITRONECTIN RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL MIGRATION; CONTROLLED STUDY; EPITHELIAL MESENCHYMAL TRANSITION; GENE SILENCING; HUMAN; HUMAN CELL; LUNG METASTASIS; MALE; METASTASIS; MOUSE; NONHUMAN; OSTEOSARCOMA; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; UPREGULATION; ANIMAL; CELL MOTION; DISEASE MODEL; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PATHOLOGY; PHENOTYPE; TUMOR CELL LINE;

ANIMALS; BIOMARKERS, TUMOR; CELL LINE, TUMOR; CELL MOVEMENT; CYSTEINE-RICH PROTEIN 61; DISEASE MODELS, ANIMAL; EPITHELIAL-MESENCHYMAL TRANSITION; ETS-DOMAIN PROTEIN ELK-1; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; MICE; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; NEOPLASM METASTASIS; OSTEOSARCOMA; PHENOTYPE; RAF KINASES; RECEPTORS, VITRONECTIN; SIGNAL TRANSDUCTION; TWIST TRANSCRIPTION FACTOR;

EID: 84934911486     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-13-236     Document Type: Article

References (59)

1. Ek ET, Choong PF: The role of high-dose therapy and autologous stem cell transplantation for pediatric bone and soft tissue sarcomas. Expert Rev Anticancer Ther 2006,6(2):225-237. 10.1586/14737140.6.2.225
2. Kempf-Bielack B, Bielack SS, Jurgens H, Branscheid D, Berdel WE, Exner GU, Gobel U, Helmke K, Jundt G, Kabisch H, Kevric M, Klingebiel T, Kotz R, Maas R, Schwarz R, Semik M, Treuner J, Zoubek A, Winkler K: Osteosarcoma relapse after combined modality therapy: an analysis of unselected patients in the Cooperative Osteosarcoma Study Group (COSS). J Clin Oncol 2005,23(3):559-568.
3. Arndt CA, Crist WM: Common musculoskeletal tumors of childhood and adolescence. N Engl J Med 1999,341(5):342-352. 10.1056/NEJM199907293410507
4. Bacci G, Ferrari S, Longhi A, Perin S, Forni C, Fabbri N, Salduca N, Versari M, Smith KV: Pattern of relapse in patients with osteosarcoma of the extremities treated with neoadjuvant chemotherapy. Eur J Cancer 2001,37(1):32-38. 10.1016/S0959-8049(00)00361-0
5. Thiery JP: Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2002,2(6):442-454. 10.1038/nrc822
6. Thiery JP, Acloque H, Huang RY, Nieto MA: Epithelial-mesenchymal transitions in development and disease. Cell 2009,139(5):871-890. 10.1016/j.cell.2009.11.007
7. Thompson EW, Newgreen DF, Tarin D: Carcinoma invasion and metastasis: a role for epithelial-mesenchymal transition? Cancer Res 2005,65(14):5991-5995. discussion 5995
8. Scheel C, Weinberg RA: Cancer stem cells and epithelial-mesenchymal transition: concepts and molecular links. Semin Cancer Biol 2012,22(5-6):396-403.
9. Yang J, Mani SA, Donaher JL, Ramaswamy S, Itzykson RA, Come C, Savagner P, Gitelman I, Richardson A, Weinberg RA: Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell 2004,117(7):927-939. 10.1016/j.cell.2004.06.006
10. Batlle E, Sancho E, Franci C, Dominguez D, Monfar M, Baulida J, Garcia De Herreros A: The transcription factor snail is a repressor of E-cadherin gene expression in epithelial tumour cells. Nat Cell Biol 2000,2(2):84-89. 10.1038/35000034
11. Vesuna F, van Diest P, Chen JH, Raman V: Twist is a transcriptional repressor of E-cadherin gene expression in breast cancer. Biochem Biophys Res Commun 2008,367(2):235-241. 10.1016/j.bbrc.2007.11.151
12. Hajra KM, Chen DY, Fearon ER: The SLUG zinc-finger protein represses E-cadherin in breast cancer. Cancer Res 2002,62(6):1613-1618.
13. Comijn J, Berx G, Vermassen P, Verschueren K, van Grunsven L, Bruyneel E, Mareel M, Huylebroeck D, van Roy F: The two-handed E box binding zinc finger protein SIP1 downregulates E-cadherin and induces invasion. Mol Cell 2001,7(6):1267-1278. 10.1016/S1097-2765(01)00260-X
14. Yang G, Yuan J, Li K: EMT transcription factors: implication in osteosarcoma. Med Oncol 2013,30(4):697.
15. Lau LF, Nathans D: Identification of a set of genes expressed during the G0/G1 transition of cultured mouse cells. EMBO J 1985,4(12):3145-3151.
16. Perbal B: CCN proteins: multifunctional signalling regulators. Lancet 2004,363(9402):62-64. 10.1016/S0140-6736(03)15172-0
17. Planque N, Perbal B: A structural approach to the role of CCN (CYR61/CTGF/NOV) proteins in tumourigenesis. Cancer Cell Int 2003,3(1):15. 10.1186/1475-2867-3-15
18. Chen CC, Lau LF: Functions and mechanisms of action of CCN matricellular proteins. Int J Biochem Cell Biol 2009,41(4):771-783. 10.1016/j.biocel.2008.07.025
19. Grzeszkiewicz TM, Lindner V, Chen N, Lam SC, Lau LF: The angiogenic factor cysteine-rich 61 (CYR61, CCN1) supports vascular smooth muscle cell adhesion and stimulates chemotaxis through integrin alpha(6)beta(1) and cell surface heparan sulfate proteoglycans. Endocrinology 2002,143(4):1441-1450.
20. Babic AM, Kireeva ML, Kolesnikova TV, Lau LF: CYR61, a product of a growth factor-inducible immediate early gene, promotes angiogenesis and tumor growth. Proc Natl Acad Sci U S A 1998,95(11):6355-6360. 10.1073/pnas.95.11.6355
21. Lin MT, Chang CC, Chen ST, Chang HL, Su JL, Chau YP, Kuo ML: Cyr61 expression confers resistance to apoptosis in breast cancer MCF-7 cells by a mechanism of NF-kappaB-dependent XIAP up-regulation. J Biol Chem 2004,279(23):24015-24023. 10.1074/jbc.M402305200
22. Tsai MS, Bogart DF, Castaneda JM, Li P, Lupu R: Cyr61 promotes breast tumorigenesis and cancer progression. Oncogene 2002,21(53):8178-8185. 10.1038/sj.onc.1205682
23. Menendez JA, Mehmi I, Griggs DW, Lupu R: The angiogenic factor CYR61 in breast cancer: molecular pathology and therapeutic perspectives. Endocr Relat Cancer 2003,10(2):141-152. 10.1677/erc.0.0100141
24. Xie D, Yin D, Tong X, O'Kelly J, Mori A, Miller C, Black K, Gui D, Said JW, Koeffler HP: Cyr61 is overexpressed in gliomas and involved in integrin-linked kinase-mediated Akt and beta-catenin-TCF/Lef signaling pathways. Cancer Res 2004,64(6):1987-1996. 10.1158/0008-5472.CAN-03-0666
25. Pilarsky CP, Schmidt U, Eissrich C, Stade J, Froschermaier SE, Haase M, Faller G, Kirchner TW, Wirth MP: Expression of the extracellular matrix signaling molecule Cyr61 is downregulated in prostate cancer. Prostate 1998,36(2):85-91. 10.1002/(SICI)1097-0045(19980701)36:2<85::AID-PROS3>3.0.CO;2-D
26. Sampath D, Zhu Y, Winneker RC, Zhang Z: Aberrant expression of Cyr61, a member of the CCN (CTGF/Cyr61/Cef10/NOVH) family, and dysregulation by 17 beta-estradiol and basic fibroblast growth factor in human uterine leiomyomas. J Clin Endocrinol Metab 2001,86(4):1707-1715.
27. Tong X, Xie D, O'Kelly J, Miller CW, Muller-Tidow C, Koeffler HP: Cyr61, a member of CCN family, is a tumor suppressor in non-small cell lung cancer. J Biol Chem 2001,276(50):47709-47714. 10.1074/jbc.M107878200
28. Croci S, Landuzzi L, Astolfi A, Nicoletti G, Rosolen A, Sartori F, Follo MY, Oliver N, De Giovanni C, Nanni P, Lollini PL: Inhibition of connective tissue growth factor (CTGF/CCN2) expression decreases the survival and myogenic differentiation of human rhabdomyosarcoma cells. Cancer Res 2004,64(5):1730-1736. 10.1158/0008-5472.CAN-3502-02
29. Lin MT, Zuon CY, Chang CC, Chen ST, Chen CP, Lin BR, Wang MY, Jeng YM, Chang KJ, Lee PH, Chen WJ, Kuo ML: Cyr61 induces gastric cancer cell motility/invasion via activation of the integrin/nuclear factor-kappaB/cyclooxygenase-2 signaling pathway. Clin Cancer Res 2005,11(16):5809-5820. 10.1158/1078-0432.CCR-04-2639
30. Lin BR, Chang CC, Chen LR, Wu MH, Wang MY, Kuo IH, Chu CY, Chang KJ, Lee PH, Chen WJ, Kuo ML, Lin MT: Cysteine-rich 61 (CCN1) enhances chemotactic migration, transendothelial cell migration, and intravasation by concomitantly up-regulating chemokine receptor 1 and 2. Mol Cancer Res 2007,5(11):1111-1123. 10.1158/1541-7786.MCR-06-0289
31. Tan TW, Yang WH, Lin YT, Hsu SF, Li TM, Kao ST, Chen WC, Fong YC, Tang CH: Cyr61 increases migration and MMP-13 expression via alphavbeta3 integrin, FAK, ERK and AP-1-dependent pathway in human chondrosarcoma cells. Carcinogenesis 2009,30(2):258-268.
32. Chen P-C, Cheng H-C, Yang S-F, Lin C-W, Tang C-H: The CCN Family Proteins: Modulators of Bone Development and Novel Targets in Bone-Associated Tumors. BioMed Res Int 2014, 2014:1-11.
33. Sabile AA, Arlt MJ, Muff R, Bode B, Langsam B, Bertz J, Jentzsch T, Puskas GJ, Born W, Fuchs B: Cyr61 expression in osteosarcoma indicates poor prognosis and promotes intratibial growth and lung metastasis in mice. J Bone Miner Res 2012,27(1):58-67. 10.1002/jbmr.535
34. Huber MA, Kraut N, Beug H: Molecular requirements for epithelial-mesenchymal transition during tumor progression. Curr Opin Cell Biol 2005,17(5):548-558. 10.1016/j.ceb.2005.08.001
35. Holbourn KP, Acharya KR, Perbal B: The CCN family of proteins: structure-function relationships. Trends Biochem Sci 2008,33(10):461-473. 10.1016/j.tibs.2008.07.006
36. Mamuya FA, Duncan MK: aV integrins and TGF-beta-induced EMT: a circle of regulation. J Cell Mol Med 2012,16(3):445-455. 10.1111/j.1582-4934.2011.01419.x
37. Schoenenberger CA, Zuk A, Kendall D, Matlin KS: Multilayering and loss of apical polarity in MDCK cells transformed with viral K-ras. J Cell Biol 1991,112(5):873-889. 10.1083/jcb.112.5.873
38. Birchmeier W, Weidner KM, Hulsken J, Behrens J: Molecular mechanisms leading to cell junction (cadherin) deficiency in invasive carcinomas. Semin Cancer Biol 1993,4(4):231-239.
39. Hay ED, Zuk A: Transformations between epithelium and mesenchyme: normal, pathological, and experimentally induced. Am J Kidney Dis 1995,26(4):678-690. 10.1016/0272-6386(95)90610-X
40. Roskoski R Jr: ERK1/2 MAP kinases: structure, function, and regulation. Pharmacol Res 2012,66(2):105-143. 10.1016/j.phrs.2012.04.005
41. Wong M, Kireeva ML, Kolesnikova TV, Lau LF: Cyr61, product of a growth factor-inducible immediate-early gene, regulates chondrogenesis in mouse limb bud mesenchymal cells. Dev Biol 1997,192(2):492-508. 10.1006/dbio.1997.8766
42. Crockett JC, Schutze N, Tosh D, Jatzke S, Duthie A, Jakob F, Rogers MJ: The matricellular protein CYR61 inhibits osteoclastogenesis by a mechanism independent of alphavbeta3 and alphavbeta5. Endocrinology 2007,148(12):5761-5768. 10.1210/en.2007-0473
43. Fromigue O, Hamidouche Z, Vaudin P, Lecanda F, Patino A, Barbry P, Mari B, Marie PJ: CYR61 downregulation reduces osteosarcoma cell invasion, migration, and metastasis. J Bone Miner Res 2011,26(7):1533-1542. 10.1002/jbmr.343
44. Lau LF: CCN1/CYR61: the very model of a modern matricellular protein. Cell Mol Life Sci 2011,68(19):3149-3163. 10.1007/s00018-011-0778-3
45. Shah PP, Fong MY, Kakar SS: PTTG induces EMT through integrin alphaVbeta3-focal adhesion kinase signaling in lung cancer cells. Oncogene 2012,31(26):3124-3135. 10.1038/onc.2011.488
46. Ramos DM, Dang D, Sadler S: The role of the integrin alpha v beta6 in regulating the epithelial to mesenchymal transition in oral cancer. Anticancer Res 2009,29(1):125-130.
47. Polyak K, Weinberg RA: Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer 2009,9(4):265-273. 10.1038/nrc2620
48. Thiery JP, Sleeman JP: Complex networks orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell Biol 2006,7(2):131-142. 10.1038/nrm1835
49. Zohn IE, Li Y, Skolnik EY, Anderson KV, Han J, Niswander L: p38 and a p38-interacting protein are critical for downregulation of E-cadherin during mouse gastrulation. Cell 2006,125(5):957-969. 10.1016/j.cell.2006.03.048
50. Shin S, Dimitri CA, Yoon SO, Dowdle W, Blenis J: ERK2 but not ERK1 induces epithelial-to-mesenchymal transformation via DEF motif-dependent signaling events. Mol Cell 2010,38(1):114-127. 10.1016/j.molcel.2010.02.020
51. Alcorn JF, Guala AS, van der Velden J, McElhinney B, Irvin CG, Davis RJ, Janssen-Heininger YM: Jun N-terminal kinase 1 regulates epithelial-to-mesenchymal transition induced by TGF-beta1. J Cell Sci 2008,121(Pt 7):1036-1045.
52. Nawshad A, Lagamba D, Polad A, Hay ED: Transforming growth factor-beta signaling during epithelial-mesenchymal transformation: implications for embryogenesis and tumor metastasis. Cells Tissues Organs 2005,179(1-2):11-23.
53. Kasza A: Signal-dependent Elk-1 target genes involved in transcript processing and cell migration. Biochim Biophys Acta 2013,1829(10):1026-1033. 10.1016/j.bbagrm.2013.05.004
54. Patki M, Chari V, Sivakumaran S, Gonit M, Trumbly R, Ratnam M: The ETS domain transcription factor ELK1 directs a critical component of growth signaling by the androgen receptor in prostate cancer cells. J Biol Chem 2013,288(16):11047-11065. 10.1074/jbc.M112.438473
55. Odrowaz Z, Sharrocks AD: The ETS transcription factors ELK1 and GABPA regulate different gene networks to control MCF10A breast epithelial cell migration. PLoS One 2012,7(12):e49892. 10.1371/journal.pone.0049892
56. Booy EP, Henson ES, Gibson SB: Epidermal growth factor regulates Mcl-1 expression through the MAPK-Elk-1 signalling pathway contributing to cell survival in breast cancer. Oncogene 2011,30(20):2367-2378. 10.1038/onc.2010.616
57. Van't Veer LJ, Weigelt B: Road map to metastasis. Natural Med 2003,9(8):999-1000.
58. Lu DY, Leung YM, Cheung CW, Chen YR, Wong KL: Glial cell line-derived neurotrophic factor induces cell migration and matrix metalloproteinase-13 expression in glioma cells. Biochem Pharmacol 2010,80(8):1201-1209. 10.1016/j.bcp.2010.06.046
59. Chiu YC, Yang RS, Hsieh KH, Fong YC, Way TD, Lee TS, Wu HC, Fu WM, Tang CH: Stromal cell-derived factor-1 induces matrix metalloprotease-13 expression in human chondrocytes. Mol Pharmacol 2007,72(3):695-703. 10.1124/mol.107.036541